Overview

SUNCIST: A Study of Calmangafodipir in Healthy Japanese and Caucasian Subjects

Status:
Completed
Trial end date:
2017-12-18
Target enrollment:
Participant gender:
Summary
Randomized, double-bline, placebo-controlled, single dose study comparing the pharmacokinetics (PK) and safety of PP095-01 in Japanese and non-Asian (eg, Caucasian) subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Egetis Therapeutics
PledPharma AB
Treatments:
Edetic Acid
Pyridoxal Phosphate